Publications by authors named "Gartrell C Bowling"
Benign adrenal cysts are relatively uncommon variants of all adrenal incidentalomas. When identified, most benign adrenal cysts are asymptomatic, which differentiates them from other functional adrenal lesions. There are various types of adrenal cysts, although the most common being an endothelial cyst.
View Article and Find Full Text PDFHemoglobin Korle-Bu (Hb KB) is a rare and likely under-reported hemoglobin (Hb) variant resulting from an unusual point mutation on the beta-globin chain. Hb KB is typically clinically silent, and there are limited reports of Hb KB heterozygosity compounded with other hemoglobinopathies that can present with varying clinical phenotypes. Here, we report a case of compound Hb KB heterozygosity with Hb S in an asymptomatic military trainee with a positive sickle cell screening test.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to explore the relationship between pre-existing poor bone mineral density (PBMD) and the risk of bone metastasis in patients with urological cancers like kidney, bladder, prostate, and testicular cancer.
- Using a large patient database, researchers found that those with PBMD had significantly higher odds of developing bone metastases shortly after their cancer diagnosis, particularly within the first week.
- The use of bisphosphonates was linked to a reduced risk of bone metastasis in these patients, indicating a possible protective effect worth investigating further.
Background: Poly ADP-ribose polymerase inhibitors (PARPis) are an important class of therapeutics for metastatic castration-resistant prostate cancer (mCRPC). Unlike hormone-based treatments for mCRPC, PARPis are not without drug-related hematological adverse events.
Objective: To review the evidence on hematological toxicities, including anemia, thrombocytopenia, and neutropenia from PARPis in prostate cancer.
Article Synopsis
- - Prostate cancer is a serious global health issue with low survival rates in advanced stages, often progressing to a castration-resistant form after initial treatment failure.
- - Current treatments mainly target androgen receptors, but there's a pressing need for new drugs that focus on the oncogenes involved in prostate cancer development, particularly E-26 transformation-specific (ETS) transcription factors.
- - Research into various targeted therapies, including small molecules and nucleic acids, shows promise in inhibiting ETS activity, which could reduce tumor growth, though more studies are needed to understand their effects on both tumor and non-tumor tissues.